Holen Sie sich die Stockscreener-App
1.12
6.67%
0.07
Vorhandelsmarkt:
1.10
-0.02
-1.79%
Mira Pharmaceuticals Inc Aktie (MIRA) Neueste Nachrichten
Retail Surge: Is MIRA Pharmaceuticals Inc a strong growth stockMarket Growth Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
MIRA Pharmaceuticals, Inc.Common Stock (NQ:MIRA) - FinancialContent
What's Going On With MIRA Pharma Stock Tuesday? - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
MIRA Pharmaceuticals Highlights Encouraging Safety Data for Mira-55 - TipRanks
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Mira Pharmaceuticals, Inc. Announces Positive Preclinical Results for Mira-55, a Non-Opioid Pain and Anxiety Treatment - Minichart
Mira Pharmaceuticals reports preclinical results for Mira-55 with no observed THC- or rimonabant-like CNS side effects - Investing.com India
MIRA’s Mira-55 shows no CNS side effects in preclinical tests - Investing.com
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies - ACCESS Newswire
MIRA Pharmaceuticals (MIRA) posts Mira-55 CNS and pain preclinical data - Stock Titan
MIRA pain drug showed morphine-like relief without THC-like effects - Stock Titan
Aug EndMonth: What is the Moat Score of MIRA Pharmaceuticals Inc2026 Macro Moves & Weekly Return Optimization Plans - baoquankhu1.vn
Momentum Shift: Can MIRA Pharmaceuticals Inc maintain its current growth rateRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Macro Review: Can MIRA Pharmaceuticals Inc maintain its current growth rateTrade Ideas & Reliable Price Breakout Signals - baoquankhu1.vn
Dividend Watch: Can MIRA Pharmaceuticals Inc deliver alphaQuarterly Profit Report & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Short Interest in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Drops By 13.9% - MarketBeat
MIRA Pharmaceuticals Inc. (MIRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Ideas: What is the Moat Score of MIRA Pharmaceuticals IncTrade Exit Summary & Entry Point Confirmation Signals - baoquankhu1.vn
MIRA Pharmaceuticals completes dosing in Ketamir-2 Phase I trial - MSN
Wall Street Recap: What are MIRA Pharmaceuticals Incs recent SEC filings showing2025 Historical Comparison & Weekly High Return Stock Forecasts - baoquankhu1.vn
Winners Losers: Can MIRA Pharmaceuticals Inc deliver alphaQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn
MIRA completes Phase 1 trial of oral NMDA drug Ketamir-2 - Investing.com Australia
MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 - ACCESS Newswire
MIRA tests oral Ketamir-2 for chemo nerve pain after safe Phase 1 - Stock Titan
MIRA Pharmaceuticals, Inc. (MIRA) Competitors - Meyka
MIRA Completes Phase 1 Trial of Ketamir-2 Therapy - TipRanks
Mira Pharmaceuticals Inc completes phase 1 dosing of Ketamir-2SEC filing - marketscreener.com
Mira Pharmaceuticals IncCompletes Phase 1 Dosing Of Ketamir-2SEC Filing - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) finishes Ketamir-2 Phase 1 dosing with encouraging safety - Stock Titan
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 29.4% in February - MarketBeat
Ideas Watch: How does MIRA Pharmaceuticals Inc compare to its peersPortfolio Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Risk Analysis: What is the Moat Score of MIRA Pharmaceuticals IncWeekly Earnings Recap & Real-Time Price Movement Reports - baoquankhu1.vn
MIRA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aug Summary: What are MIRA Pharmaceuticals Incs recent SEC filings showingJuly 2025 Opening Moves & Safe Capital Investment Plans - baoquankhu1.vn
MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M - MSN
What is MIRA Pharmaceuticals Inc. s revenue forecastEarnings Overview Report & Daily Price Action Insights - mfd.ru
MIRA PE Ratio & Valuation, Is MIRA Overvalued - Intellectia AI
What are MIRA Pharmaceuticals Inc.’s recent SEC filings showingPortfolio Value Summary & High Conviction Buy Zone Alerts - mfd.ru
How does MIRA Pharmaceuticals Inc. compare to its peersJuly 2025 PreEarnings & Daily Technical Stock Forecast Reports - mfd.ru
Lupin settles Mirabegron patent dispute with Astellas for $90 Mn - ET Pharma
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Down 6.6%Time to Sell? - MarketBeat
MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 6.6%Time to Sell? - MarketBeat
Bear Alert: How is GIGGW managing supply chain issues2025 Big Picture & Long Hold Capital Preservation Plans - baoquankhu1.vn
MIRA Pharmaceuticals initiates final dosing in phase 1 trial of Ketamir-2 - Investing.com Nigeria
MIRA Pharmaceuticals initiates final dosing in phase 1 trial of Ketamir-2 By Investing.com - Investing.com South Africa
MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study - Rutland Herald
Cancer nerve pain has no approved drugs. Oral trial nears first-phase finish - Stock Titan
User - The Chronicle-Journal
MIRA Pharmaceuticals Advances Ketamir-2 Phase 1 to Final Cohort - TipRanks
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog - Pensacola News Journal
Value Recap: What is the Moat Score of MIRA Pharmaceuticals IncWeekly Trade Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Can MIRA Pharmaceuticals Inc. stock deliver consistent earnings growthGlobal Markets & Safe Entry Zone Identification - bollywoodhelpline.com
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Sees Significant Growth in Short Interest - Defense World
Nasdaq Moves: Is DiaMedica Therapeutics Inc a cyclical or defensive stockMarket Performance Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Aug Big Picture: How does MIRA Pharmaceuticals Inc compare to its peersGap Down & Detailed Earnings Play Strategies - baoquankhu1.vn
1.19%
1.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):